Drawing for NOVO NORDISK HAEMOPHILIA & HAEMOGLOBINOPATHIES FOUNDATION

USPTO serial 79437236

NOVO NORDISK HAEMOPHILIA & HAEMOGLOBINOPATHIES FOUNDATION

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
BELL,JUNA QUEEN
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance. Monitor the opposition window. After it closes, watch for Notice of Allowance (intent-to-use) or registration (use-based).

Status 686: Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance.

Need help with NOVO NORDISK HAEMOPHILIA & HAEMOGLOBINOPATHIES FOUNDATION?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Ashly Boesche

Ashly Boesche Pattishall, McAuliffe, Newbury, Hilliard125 S. Wacker Dr.Suite 2050Chicago, IL 60606

Goods and services

ClassDescriptionStatusFirst use
036Financial sponsorship of development projects for the purpose of enhancing care for persons with haemophilia and haemoglobinopathies; charitable fund raising to promote public awareness of haemophilia and haemoglobinopathiesACTIVE—
041Training services, namely, training services for health care staff and persons with haemophilia and haemoglobinopathies and members of their families; Training services in connection with the implementation of medical care guidelines; training services for promoting awareness of haemophilia and haemoglobinopathiesACTIVE—
044Medical diagnosis, care, and treatment of persons with haemophilia and haemoglobinopathiesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 15, 2026NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 15, 2026PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 9, 2026NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Aug 19, 2026CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 13, 2026TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Aug 13, 2026CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 13, 2026TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 5, 2026RFNTREFUSAL PROCESSED BY IB—
Feb 14, 2026RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Feb 14, 2026RFRRREFUSAL PROCESSED BY MPU—
Jan 21, 2026RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jan 20, 2026CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 13, 2026DOCKASSIGNED TO EXAMINER—
Nov 21, 2025MAFRAPPLICATION FILING RECEIPT MAILED—
Nov 21, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Nov 20, 2025REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance